Nuruddin Murtuza, Roy Soma Rani, Hoque Fahmida
Chevron Eye Hospital and Research Centre, Chittagong, Bangladesh.
Orbit, Oculoplasty and Oncology Clinic, Chittagong Eye Infirmary and Training Complex, Chittagong, Bangladesh.
Oman J Ophthalmol. 2022 Mar 2;15(1):81-84. doi: 10.4103/ojo.ojo_146_21. eCollection 2022 Jan-Apr.
Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN.
眼表鳞状上皮病变（OSSN）是最常见的非色素性眼表肿瘤。α-2b干扰素（IFNα）已被证明是治疗OSSN的一种有效免疫治疗药物。我们使用病灶内注射和局部应用（36μg/ml）聚乙二醇化（peg）α-2a干扰素而非α-2b干扰素来治疗一例手术失败的复发性OSSN病例。在本病例报告中，我们分享了使用peg-IFNα-2a治疗OSSN的初步经验。根据我们简短的临床经验，peg-IFNα-2a对眼表无毒，在治疗OSSN方面具有广阔前景。
